In this episode, I discuss corneal disease and treatments with David Eveleth, PhD, the founder, president and CEO of Trefoil Therapeutics.

Brought to you by Alcon

· Welcome to another exciting episode of Eye Care insider :14

· Intro David Eveleth, PhD :47

· Eveleth's background 1:05

· What's the treatment landscape now for corneal diseases and where are we falling short for patients? 2:59

· The origins of Trefoil Therapeutics 7:27

· FGF-1: Is it just important in the endothelium or is it also important in the epithelium? 11:47

· What is your current lead investigational candidate? 14:01

· When do you expect another read out of clinical data? 21:47

· An adjunctive therapy with cataract surgery 18:27

· What is the timeline of administration to patients? 19:24

· When do you expect a readout of clinical data? 20:49

· Is it possible to use this also for the epithelium? 21:39

· What are the most important challenges facing the ophthalmic industry? What is the most important factor to look for? 24:07

· For more information about David Eveleth, PhD, and Trefoil Therapeutics, visit www.trefoiltherapeutics.com 25:53

· Corneal disease can be fixed and better vision is possible 26:44

· Thanks for listening 27:04

We'd love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. You can find follow Trefoil Therapeutics on Twitter @TrefoilThera.

David Eveleth, PhD, is the president and CEO of Trefoil Therapeutics.

Disclosures: Eveleth is the founder, CEO and shareholder of Trefoil Therapeutics. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.